Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.

Détails

ID Serval
serval:BIB_440C76FE78E2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Périodique
European Journal of Cancer
Auteur⸱e⸱s
Gianni L., Gelber S., Ravaioli A., Price K.N., Panzini I., Fantini M., Castiglione-Gertsch M., Pagani O., Simoncini E., Gelber R.D., Coates A.S., Goldhirsch A.
ISSN
1879-0852[electronic], 0959-8049[linking]
Statut éditorial
Publié
Date de publication
2009
Volume
45
Numéro
4
Pages
561-571
Langue
anglais
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The incidence of second non-breast primary cancer following adjuvant treatment was evaluated using data from patients enrolled from 1978 to 1999 in four International Breast Cancer Study Group (IBCSG) trials. The occurrence of these tumours as sites of the first failure was assessed separately for two treatment comparisons: toremifene versus tamoxifen for 5 years in 1035 patients in IBCSG Trials 12-93 and 14-93 with a median follow-up of 8 years and endocrine therapy (toremifene or tamoxifen) versus chemo-endocrine therapy (CMF or AC plus toremifene or tamoxifen) in 1731 patients from IBCSG Trials III, VII and 12-93, with a combined median follow-up of 14 years. No significant differences in second non-breast primary tumours were observed in either comparison. In particular, the incidences of second primary uterine tumours with toremifene and tamoxifen were similar and no significant increase of secondary leukaemias was observed with chemo-endocrine therapy compared with endocrine therapy.
Mots-clé
Adult, Antineoplastic Agents, Hormonal/administration & dosage, Antineoplastic Agents, Hormonal/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Breast Neoplasms/drug therapy, Breast Neoplasms/surgery, Chemotherapy, Adjuvant/adverse effects, Cohort Studies, Cyclophosphamide/administration & dosage, Cyclophosphamide/adverse effects, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Mastectomy, Middle Aged, Neoplasms, Second Primary/chemically induced, Survival Analysis, Tamoxifen/administration & dosage, Tamoxifen/adverse effects, Toremifene/administration & dosage, Toremifene/adverse effects
Pubmed
Web of science
Création de la notice
03/02/2010 11:43
Dernière modification de la notice
20/08/2019 14:48
Données d'usage